Ocean Biomedical Inc.

OCEA
$0.00 (+ $0.00 + 200.00%)
Last updated: 2026-07-08 14:28 UTC
OCEA Metrics
Exchange
🇺🇸 NASDAQ XNCM
Nasdaq Capital MarketUnited StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS67644C1045
CUSIP67644C104
Market Price0.0
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPSN/A
Market Cap$23,236
Book Value-0.56
Price to Book-0.0
Beta0.98
52w High0.01
52w Low0.0
Next Earnings DateN/A

Ocean Biomedical Inc. trades under ticker OCEA on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US67644C1045, CUSIP 67644C104.

About the Company
Ocean Biomedical Inc. is a life sciences company that focuses on developing and commercializing innovative therapeutics. The company's primary function is to bridge the gap between cutting-edge research and the practical treatment of diseases, particularly those with significant unmet medical needs. Ocean Biomedical collaborates with leading research universities and medical institutions to harness their groundbreaking discoveries for clinical applications. By doing so, they target multiple sectors within the biomedical field, including oncology, infectious diseases, and other critical therapeutic areas. The company plays a significant role in the healthcare market by potentially transforming promising scientific breakthroughs into viable medical treatments, thereby facilitating advancements in patient care and health outcomes globally. Ocean Biomedical Inc.'s work contributes to the dynamic and rapidly evolving landscape of medical science, continually pushing the boundaries of what is possible in the fight against complex diseases.
Price History
Latest News for OCEA
Ocean Biomedical Announces Grant on Patent Right for Bispecific Antibodies Targeting CHI3L1 and PD1 for Enhanced Tumor Cell Cytotoxicity in China
PROVIDENCE, R.I., March 28, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company dedicated to advancing innovative treatments for cancer, infectious diseases, and fibrosis, today announced that the China National Intellectual Property Administration (CNIPA) has granted a notice of grant on patent right for its bispecific antibodies targeting CHI3L1 and PD1, designed to enhance T cell-mediated cytotoxic effects on tumor cells. This newly issued patent will s